RadNet Inc (RDNT) Stock AnalysisRDNTRadNet Inc

RadNet, Inc. is a national provider of fixed-site diagnostic imaging services in the United States. The Company has a network over of 435 owned and/or operated outpatient imaging centers. Its Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis & treatment of diseases and disorders. Its services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures. Its Digital Health segment develops and deploys clinical applications to enhance interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics. It provides radiology information technology and artificial intelligence (AI) solutions marketed under the DeepHealth brand and teleradiology professional services. It is also a provider of AI-powered breast health solutions. It operates in the Healthcare sector (SERVICES-MEDICAL LABORATORIES industry).

RadNet Inc is currently not a strong buy due to its recent price decline and mixed financial performance. The current price is $68.80, with a forward P/E ratio of 36.63, indicating high valuation concerns. Additionally, the RSI is at 39.84, suggesting the stock is nearing oversold territory but not yet a strong buy signal. The main risk is the recent net income drop to $7.5 million in Q2 2026, down from $14.5 million a year earlier, highlighting profitability challenges.

2 analysts cover RDNT: 2 rate it Buy, 0 Hold and 0 Sell. The average price target is 90.17.